Hims & Hers Partners with Eli Lilly to Sell Obesity Medicines
The agreement provides access for prescribed patients to Lilly's obesity medicines self-pay pricing starting at $149 per month without leaving the platform.
Eli Lilly and Company and Hims & Hers Health, Inc. hentered an agreement to help expand access to Zepbound (tirzepatide) and Foundayo (orforglipron).
Under the agreement, eligible patients who receive a prescription from a licensed provider on the Hims & Hers platform will be able to access the same self-pay prices available to any patient, without leaving the platform.1 Previously patients were forced to leave the site and were directed to
How does the arrangement work?
The agreement combines Eli Lilly’s obesity medicines with Hims & Hers’ consumer platform, allowing patients to complete a consultation, receive a prescription if their provider determines it’s appropriate, and have the FDA-approved medicine shipped directly to their home in a single experience.1 Self-pay pricing starts at $149 per month for Foundayo and $299 per month for Zepbound.
As part of the agreement, the companies are committing to protect independent clinical decision-making, so providers on the Hims & Hers platform can continue to prescribe the treatment they determine is right for each patient. The companies also note that Hims & Hers have never offered access to compounded copies of Lilly’s GLP-1 medicines and has committed not to do so going forward. Back in February this year, Hims & Hers
Why are the companies pursuing this now?
Lilly frames the deal as part of a broader push to meet patients through existing digital health channels. “At Lilly, we are always looking for new ways to help more people get the medicines they need, and that means meeting patients where they already are,” says Ilya Yuffa, executive vice president and president of Lilly U.S. and global customer capabilities at Eli Lilly and Company. “Millions of people turn to Hims & Hers for their care, and through this agreement, those patients now have a simple, more direct way to get FDA-approved Lilly medicine at an affordable price if prescribed.”
Andrew Dudum, co-founder and CEO of Hims & Hers, positions the partnership as a model for industry collaboration. “Lilly is one of the most innovative pharmaceutical companies in history, and I’m incredibly proud that Hims & Hers is a part of making sure more people can access the medicines they’ve created,” he says. “By working together, we’re not just reaching more people with obesity with seamless, personal access to FDA-approved Lilly medicine. We’re showing the industry what innovators can achieve for customers everywhere when we work together to make the world well.”
What’s next?
The deal arrives as adults with obesity show growing interest in accessing prescription GLP-1 medicines through telehealth, a shift accelerated by the expanding range of FDA-approved options, including Foundayo, Lilly’s daily oral GLP-1. Scott Snyder, chief digital officer at EVERSANA,
For Lilly, the agreement extends distribution into one of the largest digital health platforms in the world at a moment when competition among obesity drugmakers and pricing pressure from compounded alternatives have made direct-to-consumer access a central battleground. how the arrangement affects volume for Zepbound and Foundayo relative to other distribution channels will likely become clearer in the companies’ coming quarterly results.
Sources
- Lilly and Hims & Hers expand access to FDA-approved Lilly medicines Eli Lilly and Company November 6, 2026,
https://investor.lilly.com/news-releases/news-release-details/lilly-and-hims-hers-expand-access-fda-approved-lilly-medicines - Lilly to sell obesity drugs directly on Hims & Hers site Reuters November 6, 2026,
https://www.reuters.com/legal/litigation/lilly-sell-obesity-drugs-directly-hims-hers-site-2026-11-06/
Related to this article
